Considering potential transaction says GSK Consumer Healthcare; Unilever confirms development

Image
Press Trust of India New Delhi
Last Updated : Nov 29 2018 | 8:55 PM IST

GlaxoSmithKline Consumer Healthcare Thursday confirmed that "consideration is being given to a potential transaction" amid reports that Unilever Plc has emerged as the top contender to acquire the nutrition business of UK-based GSK Plc.

Hindustan Unilever, the Indian arm of Unilever, confirmed that the company was in the race to acquire GlaxoSmithKline Plc's consumer healthcare nutrition products, including the popular drink Horlicks, but said it was bound by "confidentiality obligations" from disclosing details at this point of time.

In March this year, GlaxoSmithKline Plc (GSK) had announced a strategic review of Horlicks and its other consumer healthcare nutrition products following its acquisition of 36.5 per cent stake in the consumer healthcare business of Novartis for GBP 9.2 billion.

GSK is considering to sell Horlicks and other nutrition brands as part of plans to fund the acquisition.

The majority of Horlicks and other GSK nutrition products sales are generated in India by GlaxoSmithKline Consumer Healthcare (GSKCH).

"The company can confirm that consideration is being given to a potential transaction, which includes a merger of the company," GSKCH said in a clarification to BSE.

It, however, did not disclose details and the identity of potential buyer although reports suggested that Anglo-Dutch consumer goods firm Unilever PLC has emerged as the top contender for the nutrition business of GlaxoSmithKline.

In a separate clarification to BSE over the reports, Hindustan Unilever said, "With reference to this particular case, we wish to state that we are bound by the confidentiality obligations at this point in time."
The company further said,"...considering confidentiality norms, it will not be correct for us to provide any further details at this stage."
GSKCH also said, "There can be no assurance that a transaction will result from the review process nor has any decision on the matter been made by the company."

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 29 2018 | 8:55 PM IST

Next Story